A novel messenger RNA and long noncoding RNA signature associated with the progression of nonmuscle invasive bladder cancer

2018 ◽  
Vol 120 (5) ◽  
pp. 8101-8109 ◽  
Author(s):  
Yu‐hui He ◽  
Yi‐sen Deng ◽  
Pan‐xin Peng ◽  
Ning Wang ◽  
Jian‐feng Wang ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Long Noncoding Rna ◽  
Messenger Rna ◽  
Noncoding Rna ◽  
Invasive Bladder Cancer ◽  
Nonmuscle Invasive Bladder Cancer ◽  
Rna Signature

Nonmuscle-Invasive Bladder Cancer: What's Changing and What has Changed

2017 ◽  
Vol 84 (1) ◽  
pp. 1-8 ◽  
Author(s):  
Ramanitharan Manikandan ◽  
Oscar Rodriguez ◽  
Rubén Parada ◽  
Joan Palou Redorta
Keyword(s):  
Bladder Cancer ◽  
Best Practice ◽  
Disease Recurrence ◽  
Invasive Bladder Cancer ◽  
Current Status ◽  
Optimal Care ◽  
Medline Search ◽  
Select Group ◽  
The Future ◽  
Nonmuscle Invasive Bladder Cancer

Purpose Nonmuscle-invasive bladder cancer (NMIBC) is a challenging disease to manage primarily due to its varied clinical course. The management of NMIBC has witnessed a widespread change with respect to its diagnosis and treatment. Although transurethral resection (TUR) and adjuvant bacillus Calmette–Guerin (BCG) stills remain the cornerstone, newer protocols has come into vogue to achieve optimal care. On the basis of a literature review, we aimed to establish ‘what changes has already occurred and what is expected in the future’ in NMIBC. Methods A Medline search was performed to identify the published literature with respect to diagnosis, treatment and future perspectives on NMIBC. Particular emphasis was directed to determinants such as the quality of TUR and the newer modifications, Re-TUR, current status of newer macroscopic and microscopic imaging, role of urinary biomarkers, clinical, histologic and molecular predictors of high-risk disease, administration of intravesical agents, salvage therapy in BCG recurrence and the current best practice guidelines were analyzed. Results and Conclusions Optimal TUR, restaging in select group, incorporation of newer endoscopic imaging and judicious administration of intravesical chemo-immunotherapeutic agents can contribute to better patient care. Although there is a plethora of urinary markers, there is insufficient evidence for their use in isolation. The future probably lies in identification of genetic markers to determine disease recurrence, nonresponders to standard treatment and early institution of alternative/targeted therapy.

Hexylaminolevulinate Photodynamic Diagnosis for Multifocal Recurrent Nonmuscle Invasive Bladder Cancer

2009 ◽  
Vol 23 (6) ◽  
pp. 983-988 ◽  
Author(s):  
Eleanor R. Ray ◽  
Kathryn Chatterton ◽  
Kay Thomas ◽  
M. Shamim Khan ◽  
Ashish Chandra ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Invasive Bladder Cancer ◽  
Photodynamic Diagnosis ◽  
Nonmuscle Invasive Bladder Cancer

scholarly journals The long-term outcome of treated high-risk nonmuscle-invasive bladder cancer

Cancer ◽  
2012 ◽  
Vol 118 (22) ◽  
pp. 5525-5534 ◽  
Author(s):  
Francis Thomas ◽  
Derek J. Rosario ◽  
Naomi Rubin ◽  
John R. Goepel ◽  
Maysam F. Abbod ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
High Risk ◽  
Invasive Bladder Cancer ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Nonmuscle Invasive Bladder Cancer
Sign in / Sign up

Export Citation Format

Share Document